Recombinant human luteinizing hormone (r-hLH)
IMP25345
Phase 3 small_molecule completed
Quick answer
Recombinant human luteinizing hormone (r-hLH) for Hypogonadism is a Phase 3 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Hypogonadism
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed